Dogwood Q1 net loss $5.0M; Halneuron Phase 2b data due fall 2026

Dogwood Therapeutics, Inc.

Net loss of $5.0M ($0.15 per share) vs $12.2M ($8.45) in Q1 2025; R&D $2.7M, G&A $2.4M.
Cash $13.2M provides runway into Q4 2026; closed $12.5M of a $26.9M financing in Jan 2026.
Halneuron Phase 2b in CINP: 164 enrolled, top-line results expected fall 2026.
SP16 IND approved; Phase 1b in CIPPN funded by NCI, enrollment starts mid-2026.
Announced global partnership for legacy antiviral assets with potential value up to $100M to Dogwood and shareholders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.